

**HOBBS OCD**
**JUN 03 2014**
**RECEIVED**
**Analytical Results For:**

LINN OPERATING-HOBBS  
BRIAN WALL  
2130 W. BENDER  
HOBBS NM, 88240  
Fax To: (575) 738-1740

Received: 05/27/2014  
Reported: 05/29/2014  
Project Name: CAPROCK MALJAMAR UNITS  
Project Number: NONE GIVEN  
Project Location: ANGEL RANCH

Sampling Date: 05/27/2014  
Sampling Type: Soil  
Sampling Condition: Cool & Intact  
Sample Received By: Jodi Henson

**Sample ID: 1A1 CMU #10 (H401617-01)**

BTX 8021B			mg/kg		Analyzed By: MS					
Analyte	Result	Reporting Limit	Analyzed	Method Blank	BS	% Recovery	True Value QC	RPD	Qualifier	
Benzene*	<0.050	0.050	05/28/2014	ND	2.35	117	2.00	0.169		
Toluene*	<0.050	0.050	05/28/2014	ND	2.33	116	2.00	0.564		
Ethylbenzene*	<0.050	0.050	05/28/2014	ND	2.23	111	2.00	0.00243		
Total Xylenes*	<0.150	0.150	05/28/2014	ND	6.97	116	6.00	0.0216		
Total BTX	<0.300	0.300	05/28/2014	ND						

Surrogate: 4-Bromofluorobenzene (PIE) 105 % 89.4-126

Chloride, SM4500Cl-B			mg/kg		Analyzed By: AP					
Analyte	Result	Reporting Limit	Analyzed	Method Blank	BS	% Recovery	True Value QC	RPD	Qualifier	
Chloride	<16.0	16.0	05/28/2014	ND	416	104	400	3.77		

TPH 8015M		mg/kg		Analyzed By: MS						
Analyte	Result	Reporting Limit	Analyzed	Method Blank	BS	% Recovery	True Value QC	RPD	Qualifier	
GRO C6-C10	<10.0	10.0	05/28/2014	ND	212	106	200	16.2		
DRO >C10-C28	<10.0	10.0	05/28/2014	ND	228	114	200	20.7		

Surrogate: 1-Chlorooctane 122 % 65.2-140

Surrogate: 1-Chlorooctadecane 123 % 63.6-154

APPROVED FOR  
INSPECTION  
6/3/14

Cardinal Laboratories

\*=Accredited Analyte

PLEASE NOTE: Liability and Damages. Cardinal's liability and client's exclusive remedy for any claim arising, whether based in contract or tort, shall be limited to the amount paid by client for analyses. All claims, including those for negligence and any other cause whatsoever shall be deemed waived unless made in writing and received by Cardinal within thirty (30) days after completion of the applicable service. In no event shall Cardinal be liable for incidental or consequential damages, including, without limitation, business interruptions, loss of use, or loss of profits incurred by client, its subsidiaries, affiliates or successors arising out of or related to the performance of the services hereunder by Cardinal, regardless of whether such claim is based upon any of the above stated reasons or otherwise. Results relate only to the samples identified above. This report shall not be reproduced except in full with written approval of Cardinal Laboratories.



Celey D. Keene, Lab Director/Quality Manager